Found: 23
Select item for more details and to access through your institution.
Assessment of technical and clinical utility of a bead-based flow cytometry platform for multiparametric phenotyping of CNS-derived extracellular vesicles.
- Published in:
- Cell Communication & Signaling, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12964-023-01308-9
- By:
- Publication type:
- Article
Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells.
- Published in:
- OncoTargets & Therapy, 2021, v. 14, p. 1707, doi. 10.2147/OTT.S300623
- By:
- Publication type:
- Article
Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 7, p. 954, doi. 10.1093/neuonc/noz071
- By:
- Publication type:
- Article
QOLP-20. QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi218, doi. 10.1093/neuonc/noy148.906
- By:
- Publication type:
- Article
CBMT-17. NOVEL APPROACH OF UTILISING SERUM/PLASMA EV AND CELL-FREE RNA FOR TREATMENT MONITORING IN GLIOBLASTOMA PATIENTS.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi35, doi. 10.1093/neuonc/noy148.136
- By:
- Publication type:
- Article
HOUT-30. TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM).
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi119, doi. 10.1093/neuonc/noy148.498
- By:
- Publication type:
- Article
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.
- Published in:
- Oncology Reports, 2017, v. 38, n. 6, p. 3291, doi. 10.3892/or.2017.6013
- By:
- Publication type:
- Article
Corticosteroid-responsive aseptic meningitis during regorafenib treatment.
- Published in:
- Neuro-Oncology Practice, 2019, v. 6, n. 6, p. 508, doi. 10.1093/nop/npz030
- By:
- Publication type:
- Article
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
- Published in:
- Journal of Neuro-Oncology, 2023, v. 164, n. 3, p. 749, doi. 10.1007/s11060-023-04470-9
- By:
- Publication type:
- Article
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
- Published in:
- Journal of Neuro-Oncology, 2023, v. 164, n. 3, p. 607, doi. 10.1007/s11060-023-04444-x
- By:
- Publication type:
- Article
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
- Published in:
- Journal of Neuro-Oncology, 2022, v. 159, n. 1, p. 95, doi. 10.1007/s11060-022-04046-z
- By:
- Publication type:
- Article
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
- Published in:
- Journal of Neuro-Oncology, 2019, v. 144, n. 3, p. 501, doi. 10.1007/s11060-019-03246-4
- By:
- Publication type:
- Article
Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma.
- Published in:
- Genes, Chromosomes & Cancer, 2017, v. 56, n. 8, p. 639, doi. 10.1002/gcc.22467
- By:
- Publication type:
- Article
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 3, p. 787, doi. 10.1007/s00432-019-03106-8
- By:
- Publication type:
- Article
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 8, p. 1581, doi. 10.1007/s00432-018-2671-z
- By:
- Publication type:
- Article
The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2016, v. 142, n. 8, p. 1825, doi. 10.1007/s00432-016-2187-3
- By:
- Publication type:
- Article
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2016, v. 142, n. 7, p. 1581, doi. 10.1007/s00432-016-2161-0
- By:
- Publication type:
- Article
Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 1, p. 89, doi. 10.1002/cam4.966
- By:
- Publication type:
- Article
Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 19, p. 7211, doi. 10.3390/ijms21197211
- By:
- Publication type:
- Article
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression.
- Published in:
- International Journal of Cancer, 2023, v. 152, n. 2, p. 308, doi. 10.1002/ijc.34261
- By:
- Publication type:
- Article
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA‐09 trial.
- Published in:
- International Journal of Cancer, 2021, v. 148, n. 7, p. 1695, doi. 10.1002/ijc.33363
- By:
- Publication type:
- Article
Extracellular Vesicle Separation Techniques Impact Results from Human Blood Samples: Considerations for Diagnostic Applications.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 17, p. 9211, doi. 10.3390/ijms22179211
- By:
- Publication type:
- Article